IDiyas

For the Inventor, By the Inventor

Belle Mead, NJ, United States of America

Nicolas Cuniere

LinkedIn
USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 9.3

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:

goldMedal9 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
silverMedal1 out of 2,076 
 
Janssen Pharmaceutica Nv
 patents
where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...
Loading Chart...
9 patents (USPTO):
1. 12378246 - Synthetic options towards the manufacture of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl} - 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one (2025-08-05),
2. 12129264 - Crystalline forms of a PAR4 inhibitor (2024-10-29),
3. 9518058 - Process for the preparation of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (2016-12-13),
4. 7820820 - Method of preparation of azaindole derivatives (2010-10-26),
5. 7598380 - Method of preparation of azaindole derivatives (2009-10-06),
6. 7579472 - Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones (2009-08-25),
7. 7435821 - Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones (2008-10-14),
8. 7396932 - Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones (2008-07-08),
9. 7304157 - Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones (2007-12-04),

Title: The Innovative Mind of Nicolas Cuniere

Introduction

Nicolas Cuniere, an accomplished inventor based in Belle Mead, NJ, USA, has made significant contributions to the field of pharmaceuticals. With a portfolio of 8 patents to his name, Cuniere's work focuses on developing innovative compounds aimed at treating various medical conditions.

Latest Patents

Among Cuniere's latest inventions are two notable patents that showcase his expertise. The first patent involves the development of crystalline forms of a PAR4 inhibitor. This invention relates to co-crystals of a compound where the co-former molecule is either succinic acid or citric acid. The invention provides processes for the preparation of these co-crystals, including pharmaceutical compositions and methods for treating or preventing thromboembolic disorders.

The second patent pertains to an improved process for synthesizing the compound N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide. This compound is currently undergoing clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia, and primary myelofibrosis.

Career Highlights

Nicolas Cuniere has established his career at Bristol-Myers Squibb Company, a renowned pharmaceutical giant. His work at this prestigious company highlights his dedication to advancing medical science and providing innovative solutions for patient care.

Collaborations

Cuniere's collaborative efforts with notable colleagues further emphasize his impact in the field. He has worked alongside talented professionals such as Lucius Rossano and Boguslaw Mudryk, contributing to a shared vision of driving pharmaceutical innovation.

Conclusion

Nicolas Cuniere stands out as a prominent inventor in the pharmaceutical industry. His dedication to developing innovative compounds and treatments reflects his commitment to improving healthcare outcomes. With a strong patent portfolio and collaborations with esteemed colleagues, Cuniere continues to leave a lasting mark on the world of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…